New industry forecasts project the global pharmaceutical market will surpass $1.9 trillion by 2027, driven by rapid expansion in biologics, specialty drugs, and growing healthcare access in Asia-Pacific and Latin America.
Key growth drivers include the surge in GLP-1 receptor agonists, continued biosimilar adoption, and increased R&D investment following pandemic-era lessons. The Asia-Pacific region is expected to contribute over 30% of new market growth.
CDMOs are positioned to benefit significantly, as large pharma companies continue to outsource manufacturing capacity to meet demand.